Personal & Confidential. Xxxxxxx Xxxxxx Dear Xxxxxxx, I am pleased to be able to communicate the following information regarding your compensation in the role of Chief Executive Officer at Bit9, Inc. In recognition of your continued efforts, effective January 1, 2016 your annual on target earnings will be increased from $595,000 to $750,000. Your OTE will consist of a base salary of $375,000 and a target annual bonus of 100%. The January 15, 2016 payroll will reflect the base salary and your bonus payment will follow the terms of the Executive bonus plan. In addition to the above compensation, and subject to Board of Directors approval, you are eligible for and will receive stock options in accordance with the Company’s Incentive Stock Option Plan. You will be granted an option to purchase 1,000,000 shares of the Company’s stock at a price per share equal to the fair market value at the time of Board approval. The option grant shall be subject to all terms, vesting schedules and other provisions set forth in the Plan and in a separate option agreement. On behalf of the entire organization, I would like to communicate our gratitude for your contributions to the company. I look forward to another year of continued growth and success for Bit9 under your leadership. /s/ Xxxx Xxxxxxxx Xxxx Xxxxxxxx This Amendment (“Amendment”) is entered into effective January 1, 2018 , by and between Carbon Black, Inc., f/k/a Bit9, Inc. (the “Company”), and Xxxxxxx Xxxxxx (the “Executive”).
Personal & Confidential. Mr. Xxxxxx X. Xxxx [address redacted] Re: Special Advisor Terms & Conditions of Employment Dear Maxxxx, This Letter Agreement confirms the terms of your continued employment with Western Digital Technologies, Inc. (the “Company”) in light of your announcement that you intend to retire effective September 13, 2019.
Personal & Confidential. Dear Xxx: This letter will confirm the terms of your employment with Smartcool Systems Inc. ("Smartcool"). By signing this letter agreement (the "Agreement") you accept the following terms and conditions:
Personal & Confidential. Xx. Xxxxxxx Xxx 00 Xxxxxx Xxxxxx, Xxxxxxxxxx 00000 Re: Masimo Corporation 2007 Executive Severance Protection Plan Participation Agreement Dear Yongsam: This letter relates to the 2007 Executive Severance Protection Plan (the “Plan”) that we, Masimo Corporation have adopted. Through this letter, you are being offered the opportunity to become a participant in the Plan, and thereby to be eligible to receive the basic, change in control, and voluntary severance benefits described below. A copy of the Plan is attached to this letter. You should read it carefully and become comfortable with its terms and conditions, and those set forth below. If you choose to sign below, you will be establishing a Participation Agreement within the meaning of the Plan, and you will thereby be acknowledging and agreeing to the following provisions:
Personal & Confidential. Nothing contained in this Agreement or in the Plan shall confer upon the Participant any right to continue in the employment of, or remain in the service of, Ashland or its subsidiaries. Information about the Participant and the Participant’s participation in the Plan may be collected, recorded and held, used and disclosed by and among Ashland, its subsidiaries and any third party Plan administrators as necessary for the purpose of managing and administering the Plan. The Participant understands that such processing of this information may need to be carried out by Ashland, its subsidiaries and by third party administrators whether such persons are located within the Participant’s country or elsewhere, including the United States of America. By accepting this Award, the Participant consents to the processing of information relating to the Participant and the Participant’s participation in the Plan in any one or more of the ways referred to above. The Participant consents and agrees to electronic delivery of any documents that Ashland may elect to deliver (including, but not limited to, prospectuses, prospectus supplements, grant or award notifications and agreements, account statements, annual and quarterly reports, and all other forms of communications) in connection with this and any other award made or offered under the Plan. The Participant understands that, unless earlier revoked by the Participant by giving written notice to Ashland at 00 X. XxxxxXxxxxx Xxxx., Xxxxxxxxx, XX 00000 Attention: Xxxx Xxxxxxxxx, this consent shall be effective for the duration of the Award. The Participant also understands that the Participant shall have the right at any time to request that Ashland deliver written copies of any and all materials referred to above at no charge. This Award is granted under, and is subject to, all the terms and conditions of the Plan, including, but not limited to, the forfeiture provision of Section 16(H) of the Plan. In consideration of this Award, the Participant agrees that without the written consent of Ashland, the Participant will not (i) engage directly or indirectly in any manner or capacity as principal, agent, partner, officer, director, employee or otherwise in any business or activity competitive with the business conducted by Ashland or any of its subsidiaries; or (ii) perform any act or engage in any activity that is detrimental to the best interests of Ashland or any of its subsidiaries, including, without limitation, (aa) so...
Personal & Confidential. Xx. Xxxxxxx X. Rousseau President and Chief Executive Officer St. Jude Medical 0000 Xxx Xxxxx Xx., Xxxx. 0, Xxx. 000 Xxxxxx, XX 00000 Dear Xxxx: Xxxxxx Laboratories (“Abbott”) views you as an integral part of its organization and the success of the merger, and we look forward to working with you. As you know, Abbott entered into a Merger Agreement on April 27, 2016, by and among Abbott, an Illinois corporation, St. Jude Medical Inc., a Minnesota corporation (“St. Jude Medical”), Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the “Merger Agreement”), that will result in your employer becoming a wholly-owned subsidiary of Abbott at the closing of the transaction (“Effective Date”). This Retention Agreement (the “Agreement” or the “Retention Agreement”) is contingent upon the closing of the transaction and only effective as of the Effective Date. This Retention Agreement does not supersede any rights you may have to merger consideration under the Merger Agreement.
Personal & Confidential. This Agreement constitutes the complete understanding between you and the Company concerning all matters affecting your employment with the Company and the termination thereof. If you accept and do not timely revoke this Agreement, it supersedes all prior agreements, understandings and practices concerning such matters between you and the Company, including, but not limited to, any personnel documents, handbooks, policies, incentive or bonus plans or programs, and any prior customs or practices of the Company; provided, however, that the Restrictive Covenants shall survive this Agreement and your separation from employment with the Company as provided in Paragraph 3(F) above.
Personal & Confidential data This term describes personal information about identified or identifiable individuals, which should be kept private or secret. For the purposes of this report ‘personal’ includes the Data Protection Xxx 0000 s.1 definition of personal data, but it is adapted to include dead as well as living people and ‘confidential’ includes both information ‘given in confidence’ and ‘that which is owed a duty of confidence’ and is adapted to include ‘sensitive personal data’ as defined in the Data Protection Xxx 0000. This term was introduced in the Caldicott 2 review and is not the term used across the Health economy.
Personal & Confidential. Xxx Xxxxx, President & CEO Xxxxx Xxxxxxx, Chairman Xxxxx.xxx, Inc. 000 Xx. Xxxxxxx Xxxxxx Xxxx, 0xx Xxxxx Xxxxxxxx, XX X0X 0X0 Dear Guy & Xxxxx: Xxxxxxxx Curhan Ford & Co. (“MCF”) is pleased to act as financial advisor to Xxxxx.xxx, Inc. (the “Company”). We will provide investment banking services to the Company which may include: (i) representing the Company in its efforts to obtain financing in the form of a private investment in either (a) public equity, or (b) convertible debt or equity (a “PIPE” or “Capital Raising Transaction”), (ii) assisting the Company in identifying acquirers (the “Acquirer”) and evaluating, prioritizing, negotiating proposals to purchase the Company, in whole or part (a “Sale Transaction”), and (iii) assisting the Company in acquiring various potential acquisition targets (a “Target”) (in one or a series of transactions), by purchase, merger, consolidation and other business combination involving all or substantial amount of the business, securities, assets of a Target (an “Acquisition Transaction”).
Personal & Confidential. Xx. Xxxx X. Langenbahn Dear Xxxx, This Amended Letter Agreement (the “Amendment”) modifies the terms of the May 2, 2018 Letter Agreement between you and NCR (the “May Letter”). XXX Xxxxxxxxxxx is referred to below as “NCR” or “the Company.” Except as expressly modified below, the terms of the May Letter remain enforceable, and except as set out in this Amendment, to the extent there is any conflict between the terms of this Amendment and any other written agreement between NCR and you, including the May Letter, the terms of this Amendment shall control.
